Valneva Engages Investors Ahead of Major Conference
Valneva SE, a noteworthy player in the vaccine industry, is set to engage with its investors during the prestigious J.P. Morgan Healthcare Conference. This annual gathering will take place in early January, and Valneva's management team will hold significant discussions with shareholders and institutional investors.
Key Management Presentations
The CEO, Thomas Lingelbach, along with CFO Peter Bühler, will present on various topics related to the company's impressive vaccine portfolio. They project revenues between €160 and €170 million for 2024, highlighting the strength of their commercial offerings. Furthermore, they will share insights on crucial developments from their clinical pipeline, including the awaited data release for their Lyme disease vaccine.
Investor Meetings
Investors interested in gaining a deeper understanding of Valneva's business can schedule one-on-one meetings with the management team. The investor relations department offers opportunities for dialogue to discuss the company's future direction and clinical advancements. Interested parties can easily reach out via the contact email provided by the company.
About Valneva SE
Valneva is a specialized vaccine development company that focuses on creating vaccines for infectious diseases with significant unmet medical needs. Their approach is unique due to their specialized knowledge across multiple vaccine modalities, aiming to deliver innovative vaccine solutions globally. Among their achievements is the world's first approved chikungunya vaccine, which solidifies their position in the vaccine market.
Company Achievements and Pipeline
Valneva has successfully brought multiple vaccines from research phases to clinical approvals, showcasing their robust pipeline. The company is advancing the only Lyme disease vaccine candidate in late-stage development in partnership with Pfizer, alongside a promising Shigella vaccine candidate. The strategic focus on these vaccines aims to tackle pressing global health challenges, including Zika virus concerns.
Continuous Growth Through Revenue
The growth in commercial revenues is pivotal for Valneva, as it supports their ongoing research and development efforts. This financial stability is key as they explore new avenues and potential partnerships to further their mission of producing vaccines that meet critical health needs worldwide.
Contacting Valneva
For investors and media inquiries, Valneva provides dedicated contacts to facilitate communication. Laetitia Bachelot-Fontaine oversees global communications and investor relations, ready to address any queries that may arise. Joshua Drumm, Ph.D., plays a vital role in global investor relations, ensuring that investment perspectives are sufficiently catered to.
Frequently Asked Questions
What is the focus of Valneva's vaccine development?
Valneva specializes in creating prophylactic vaccines for infectious diseases, focusing on unmet medical needs.
When is the J.P. Morgan Healthcare Conference taking place?
The J.P. Morgan Healthcare Conference occurs in early January 2025.
Who from Valneva will be attending the conference?
The CEO and CFO of Valneva will be attending to present on the company’s commercial portfolio.
How can investors schedule meetings with Valneva?
Investors can contact Valneva's investor relations department via the provided email for scheduling meetings.
What key products does Valneva offer?
Valneva markets three proprietary travel vaccines and is advancing significant candidates including Lyme disease and Shigella vaccines.
